Spots Global Cancer Trial Database for primary peritoneal
Every month we try and update this database with for primary peritoneal cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | NCT02440425 | Ovarian Cancer | Pembrolizumab Paclitaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian | NCT01952249 | Primary Periton... | Demcizumab Taxol | 21 Years - 90 Years | Mereo BioPharma | |
| A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers | NCT01659554 | Recurrent Ovari... Fallopian Tube ... | Cisplatin Doxorubicin | 18 Years - | Columbia University | |
| Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian | NCT01219777 | Ovarian Cancer Primary Periton... Fallopian Tube ... | carboplatin Bevacizumab Paclitaxel | 18 Years - 90 Years | Ohio State University Comprehensive Cancer Center | |
| Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma | NCT00183794 | Ovarian Carcino... Peritoneal Neop... | Docetaxel and G... | 18 Years - | University of Southern California | |
| A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens | NCT02354586 | Ovarian Neoplas... Ovarian Cancer | Niraparib | 18 Years - | Tesaro, Inc. | |
| A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | NCT00421889 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Bladder Cancer | belinostat Paclitaxel Carboplatin | 18 Years - | Valerio Therapeutics | |
| Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | NCT02440425 | Ovarian Cancer | Pembrolizumab Paclitaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Intraoperative Detection of Lesions Using PET (Positron Emission Tomography) Probe During Secondary Cytoreductive Surgery for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer | NCT01826227 | Ovarian Cancer Fallopian Tube Primary Periton... | Positron Emissi... 18F-Fluoro-2-de... Cytoreductive s... | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | NCT00421889 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Bladder Cancer | belinostat Paclitaxel Carboplatin | 18 Years - | Valerio Therapeutics | |
| A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens | NCT02354586 | Ovarian Neoplas... Ovarian Cancer | Niraparib | 18 Years - | Tesaro, Inc. | |
| A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian | NCT01952249 | Primary Periton... | Demcizumab Taxol | 21 Years - 90 Years | Mereo BioPharma |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
